Form 4: Benitec Biopharma Director Acquires Stock Options

Benitec Biopharma Director Sharon Mates acquired 28,517 stock options with an exercise price of $15.78, vesting by November 2026.

Summary

• Sharon Mates, a Director of Benitec Biopharma Inc. (BNTC), acquired 28,517 derivative securities in the form of options.
• The transaction date for this acquisition was November 5, 2025.
• Each option has an exercise price of $15.78.
• The options are exercisable into 28,517 shares of Common Stock.
• The options will vest in full on the earlier of immediately prior to the Issuer's 2026 annual meeting of stockholders and November 5, 2026.
• The expiration date for these options is November 5, 2035.
• The transaction was not made pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed as a positive signal, indicating confidence in the company's future prospects and aligning the director's interests with those of shareholders. The absence of a 10b5-1 plan suggests a direct decision to acquire, which can be interpreted as a stronger signal of confidence.

Positives

• A Director acquiring options can signal confidence in the company's future performance and stock appreciation potential.
• The options have a long expiration date (November 5, 2035), providing ample time for the company's value to grow.

Future Outlook

The acquisition of options by a director, with a vesting schedule extending to November 2026, indicates a long-term incentive for the director to contribute to the company's future success and stock performance. The options' expiration in 2035 provides a significant window for potential value realization.

Industry Context

This filing is a standard disclosure of an insider transaction, common across all industries, particularly in biotechnology where equity compensation is a key component of executive and director remuneration. It reflects a director's personal stake in the company's future, which is a common practice to align interests with shareholders.

Management Changes

Related Party Transactions

• Sharon Mates, a Director of Benitec Biopharma Inc., acquired stock options from the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this transaction positively as it demonstrates a director's increased vested interest in the company's long-term success.
• The options serve as an incentive for the director to enhance shareholder value.

Next Steps

• The options will vest in full on the earlier of immediately prior to Benitec Biopharma Inc.'s 2026 annual meeting of stockholders and November 5, 2026.

Key Dates

Keywords

Benitec Biopharma, BNTC, Sharon Mates, stock options, insider transaction, Form 4, director compensation, equity compensation